NCT04699838 2026-01-02
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06597513 2024-10-15
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1/2 Not yet recruiting
NCT06323265 2024-03-27
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Hebei Medical University Fourth Hospital
Recruiting
NCT05055947 2022-01-25
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Completed
NCT05001412 2021-08-12
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT04790539 2021-03-10
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04213937 2019-12-30
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT02011087 2018-07-05
Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy
Wake Forest University Health Sciences
Phase NA Terminated
NCT02194049 2018-01-09
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT02972320 2016-11-23
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
China Medical University, China
Phase 2 Unknown